Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Pomalyst showcase 6.5


Published on

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Pomalyst showcase 6.5

  1. 1. POMALYST®(pomalidomide)Drug Showcase
  2. 2. Introduction Brand name: POMALYST® Generic name: pomalidomide Approval: 2013 Manufacturer: Celgene Corp
  3. 3. Indication, Dosage & Administration
  4. 4. Indication POMALYST is indicated for the treatment of multiple myeloma in patientswho have:◦ Received at least two prior therapies, including lenalidomide andbortezomib, and◦ Demonstrated disease progression on or within 60 days of completion ofthe last therapy
  5. 5. Dosage and Administration Recommended Dose◦ 4 mg orally once daily on Days 1-21 of repeated 28-day cycle Administration◦ To be administered until disease progression◦ Must be administered with dexamethasone◦ Must be taken with water◦ Should be taken without food (either 2 hours before or after a meal) Dose Modifications◦ Please see full Prescribing Information for dose modification guidelinesassociated with: Hematologic toxicities: neutropenia or thrombocytopena◦ Grade 3 or 4 toxicities (other than neutropenia or thrombocytopenia) Hold POMALYST When toxicity has resolved to Grade 2 or less, restart at 1 mg less thanprevious dose Discontinue if toxicities occur after dose reduction to 1 mg
  6. 6. Use in Specific Populations
  7. 7. Considerations for Special PopulationsPatient Group RecommendationsPregnancy Category X• POMALYST is contraindicated during pregnancy• If used during pregnancy or if patient becomespregnant during treatment, patient should be apprisedof the potential hazard to the fetus• If pregnancy occurs during treatment, discontinuedrugNursing mothers • It is unknown whether or not POMALYST is excreted inhuman milk• Decision to discontinue nursing or discontinue therapyshould be made considering the importance of thedrug to the motherPediatric Safety and effectiveness has not been established inpatients <18 years of age
  8. 8. Considerations for Special Populations (cont.)Patient Group RecommendationsFemales ofReproductivePotential & Males• Females of reproductive potential must avoidpregnancy by abstaining or using two methods ofreliable birth control• Contraception should begin 4 weeks before initiatingPOMALYST, during therapy and 4 weeks afterdiscontinuing therapyGeriatric • No dose adjustment is required based on age• In the study, patients >65 years of age were morelikely to experience pneumoniaRenal Impairment • Safety and efficacy have not been evaluated• Avoid use in patients with serum creatinine >3 mg/dLHepatic Impairment • Safety and efficacy have not been evaluated• Avoid use in patients with serum bilirubin >2 mg/dLand AST/ALT >3x upper limits of normal
  9. 9. Clinical Pharmacology
  10. 10. Mechanism of Action POMALYST is an immunomodulatory agent with antineoplastic activity◦ Thalidomide analogue As shown in in vitro celullar assays◦ Inhibited proliferation of lenalidomide-resistant multiple myeloma celllines◦ Induced tumor cell apoptosis when combined with dexamethasone inboth lenalidomide-sensitive and lenalidomide-resistant cell lines◦ Enhanced T cell- and natural killer cell-mediated activity◦ Inhibited monocyte production of pro-inflammatory cytokines (eg, TNF-alpha and interluekin-6)
  11. 11. PharmacokineticsParameters ValuesTime to Peak 2-3 hoursVolume of distribution 62L-138L (steady state)Protein binding • 12% to 44%• Not concentration dependentMetabolism • Hepatic• Primarily via CYP1A2, CYP3A4Half-life elimination • 9.5 hours (healthy patients)• 7.5 hours (multiple myeloma patients)Excretion • Feces: 15%• Urine: 73%
  12. 12. Drug Interactions No formal studies have been completed CYP3A, CYP1A2, P-gp inhibitors◦ Co-administration with strong CYP3A, CYP1A2, or P-gp inhibitors couldincrease exposure to POMALYST◦ Combination should be avoided CYP3A, CYP1A2, P-gp inducers◦ Co-administration with strong CYP3A, CYP1A2, or P-gp inducers coulddecrease POMALYST exposure◦ Combination should be avoided Dexamethasone◦ Did not affect POMALYST pharmacokinetics Smoking◦ May reduce effectiveness of POMALYST
  13. 13. Warnings & Precautions
  14. 14. Contraindications, Warnings and Precautions Contraindications◦ POMALYST is contraindicated in women who are pregnant◦ If drug is used during pregnancy or patient becomes pregnant, patient shouldbe apprised of the risk to the fetus Embryo-Fetal Toxicity◦ POMALYST is a thalidomide-analogue; thalidomide causes severe birth defectsor embryo-fetal death◦ Pregnancy should be avoided during POMALYST therapy and at least 4 weeksafter completing therapy◦ POMALYST is present in male semen Males must always use latex or synthetic condoms during sexual contactwith females of reproductive potential during and 28 days after therapy Males taking POMALYST should not donate sperm◦ Blood donation Blood should not be donated during treatment and up to 1 month aftercompleting treatment since exposed blood may be transferred to a pregnantfemale
  15. 15. POMALYST REMS™ Program Due to embyro-fetal risk, POMALYST is only available through POMALYSTREMS Requirements include:◦ Prescribers must be certified with the REMS program◦ Patients must sign a Patient-Prescriber agreement and comply withREMS requirements Includes pregnancy testing and contraception requirements◦ Pharmacist must be certified with the REMS program May only dispense POMALYST to patients authorized to receivePOMALYST15
  16. 16. Warnings and Precautions Venous Thromboembolism◦ Consider concomitant anti-coagulation prophylaxis based onpatient’s risk Hematologic Toxicity◦ Neutropenia, anemia, andthrombocytopenia were mostcommonly reported◦ Monitor complete blood countsweekly for first 8 weeks, thenmonthly thereafter◦ Dose may require adjustment orholding Hypersensitivity◦ Risk may be higher in patientswho experienced hypersensitivitywith thalidomide or lenalidomide Dizziness and Confusional State◦ Patients should avoid anymedications or situations thatmay cause dizziness or lead toconfusion without proper medicaladvice Neuropathy◦ Patients may experienceneuropathy or peripheralneuropathy Second Primary Malignancy Risk◦ Cases of acute myelogenousleukemia have been reported inpatients receiving POMALYST16
  17. 17. Clinical Safety & Efficacy
  18. 18. Trial 1 Information Objective◦ Evaluate the safety and efficacy of POMALYST alone or in combination with lowdose dexamethasone (Low-dose Dex) Study Design◦ Multicenter, randomized, open label, phase 2 study Patient Population and Treatment◦ Patients enrolled had relapsed multiple myeloma, were refractory to their lastmyeloma therapy and received lenalidomide and bortezomib Relapse was defined as achieving at least stable disease for at least onetreatment cycle to at least one prior regimen before disease progressed Refractory was defined as disease progression on or within 60 days of lasttherapy◦ Regimen: POMALYST 4mg, once daily for 21 days (of 28-day cycle), alone orin combination with low dose dexamethasone (Low dose Dex) Low dose Dex schedule: Days 1, 8, 15 and 22 of 28-day cycle Patients ≤75 years of age received 40 mg daily; >70 years of age received20 mg daily
  19. 19. Trial 1: Results Overall response rate did not differ based on prior anti-myeloma therapy19Response POMALYST*(N=108)POMALYST/Low doseDex (N=113)Overall Response Rate,n (%)(95% CI)8 (7.4%)(3.3-14.1)33 (29.2%)(21.0-38.5)Complete Response,n (%)0 (0%) 1 (0.9%)Partial Response,n (%)8 (7.4%) 32 (28.3%)Duration of Response,Median (months),(95% CI)NE 7.4(5.1-9.2)*Results are prior to the addition of dexamethasone.CI=confidence interval; NE=not established (median has not yet been reached).
  20. 20. Common Adverse Events, >25%POMALYST(N = 107)POMALYST + Low dose Dex(N=112)• Fatigue and asthenia (55%)• Neutropenia (52%)• Anemia (38%)• Thrombocytopenia (25%)• Constipation (36%)• Diarrhea (34%)• Nausea (36%)• Upper respiratory tract infection(32%)• Back pain (32%)• Dyspnea (34%)• Fatigue and asthenia (63%)• Pyrexia (30%)• Neutropenia (47%)• Anemia (39%)• Constipation (35%)• Diarrhea (33%)• Pneumonia (29%)• Upper respiratory tract infection(25%)• Back pain (30%)• Dyspnea (45%)
  21. 21. Drug Storage & Supply
  22. 22. Supply and Pricing Specifications How suppliedo 1-mg, 2-mg, 3-mg, and 4-mg capsules: 21-count and 100-count bottle Storage and Handing◦ Store at room temperature◦ Capsules should not be opened or crushed◦ If powder comes in contact with skin, wash immediately withsoap and water◦ If powder comes in contact with mucous membranes, flush withwater Drug Pricingo AWP/unit price: $596.88/capsule
  23. 23. References POMALYST® (pomalidomide) [package insert]. CelgeneCorporation. Summit, NJ. Truven Health Analytics. Red Book Online® Search. Micromedex.